

CANCER ADVANCES PRESENTING AT NCI CONFERENCE SEPT 22-23

On September 22 and 23, the Center of Excellence in Immunology at the Center for Cancer Research, National Cancer Institute (NCI) will host the *Cancer Immunology and Immunotherapy: Building on Success* conference at the National Institute of Health in Bethesda, Maryland. The conference will host leaders in translational and clinical research to discuss the most cutting edge immunological approaches and advances in preventing and treating cancer. The program is divided into five main sessions:

- T Cell Transfer Immunotherapy
- Immunotherapy-based Genetic Engineering of Lymphocytes
- Vaccine-based Therapies
- Transplantation-based Therapies
- Immune-modulatory Approaches

Representatives from Cancer Advances have been selected to give a poster presentation on its novel, anti-gastrin antibody (AGA) named Polyclonal Antibody Stimulator (PAS) in the treatment of advanced pancreatic cancer. As gastrin hormone is trophic to *in vitro* pancreatic cancer, the anti-proliferative and anti-metastatic properties of PAS make it a promising therapeutic option. In a group sequential trial of over 150 subjects, PAS demonstrated a safe and well-tolerated profile. It also showed a statistically significant prolonged survival time, and evidence of inhibition of tumor progression. This immunotherapy has the potential to provide a relatively nontoxic alternative to subjects who may not be suitable for or refuse to take cytotoxic chemotherapy.

Visit at Washington DC's cutting-edge oncology conference to learn more about the success of PAS. We look forward to seeing you there!

For more information about Cancer Advances: <http://www.canceradvancesinc.com/>

For more information about the NCI Cancer Immunology and Immunotherapy conference: <http://web.ncifcrf.gov/events/Immunotherapy2011/>